Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in inflammatory bowel disease patients: a nationwide Danish cohort study

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

S. B. Thomsen*¹, K. H. Allin², J. Burisch², C. B. Jensen², S. Hansen², L. L. Gluud¹, K. Theede¹, M. Kiszka-Kanowitz¹, A. M. Nielsen¹, T. Jess²

Created: Friday, 22 February 2019, 9:41 AM

DOP88: Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in Inflammatory Bowel Disease patients: A nationwide Danish cohort study

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Sandra Bohn Thomsen

Created: Tuesday, 28 May 2019, 3:32 PM

Thiopurines (AZA / MP), Morbidity, Mortality

Files: 1

DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn's disease

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Lin, S.(1,2)*;Hannon, E.(3);Waring, J.F.(4);Reppell, M.(4);Smaoui, N.(4);Pivorunas, V.L.(4);Guay, H.(4);Chanchlani, N.(1,2);Bewshea, C.(2);Bai, B.Y.H.(5,6);Kennedy, N.A.(1,2);Goodhand, J.R.(1,2);Mill, J.(3);Ahmad, T.(1,2);

Created: Friday, 14 July 2023, 10:43 AM

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Nicholas Alexander Kennedy

Created: Friday, 14 July 2023, 2:22 PM

DOP88: Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s Disease patients

Year: 2020

Source: ECCO'20 Vienna

Authors: Zixiang Lim

Created: Tuesday, 23 June 2020, 5:40 PM

DOP88: Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s Disease patients

Year: 2020

Source: ECCO'20 Vienna

Authors: Zixiang Lim

Created: Tuesday, 23 June 2020, 4:58 PM

Files: 1

DOP89 Pre-treatment mucosal inflammatory and wound healing gene programmes reveal mechanisms associated with future stricturing behaviour during 5-year follow-up in paediatric Crohn’s disease

Year: 2020

Source:

ECCO'20 Vienna

Authors:

Y. Haberman Ziv¹, P. Minar¹, R. Karns¹, P. Dexheimer¹, S. Ghandikota¹, S. Tegge¹, D. Shapiro¹, B. Shuler¹, S. Venkateswaran², T. Braun³, B. Aronow¹, G. Gibson⁴, J. Hyams⁵, S. Kugathasan², A. Jegga¹, L. Denson¹, CCF sponsored RISK Study

Created: Thursday, 30 January 2020, 10:12 AM

DOP89: Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial

Year: 2021

Source: ECCO'21 Virtual

Authors: Zoller, H.(1);Wolf, M.(2);Blumenstein, I.(3);Primas, C.(4);Lindgren, S.(5);Thomsen, L.L.(6);Reinisch, W.(4);Iqbal, T.(7)

Created: Wednesday, 2 June 2021, 4:12 PM

DOP89: Final growth in paediatric Crohn's disease is impaired also in the era of biologics: a population-based analysis from the epiIIRN administrative cohort

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

A. Assa¹, S. Cohen², N. Asayag*³, N. Dan⁴, G. Focht⁴, O. Ledder⁴, N. Lederman⁵, E. Matz⁶, A. Cahan⁷, R. Balicer⁸, B. Feldman⁸, I. Brufman⁸, D. Turner⁴

Created: Friday, 22 February 2019, 9:41 AM

DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Mathurin Fumery

Created: Friday, 14 July 2023, 2:22 PM

DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Fumery, M.(1)*;Nancey, S.(2);Nachury, M.(3);Allez, M.(4);Rouillon, C.(5);Boureille, A.(6);Altwegg, R.(7);Serrero, M.(8);Vuitton, L.(9);Bouguen, G.(10);Abitbol, V.(11);Boualit, M.(12);Biron, A.(13);Panis, Y.(14);Laharie, D.(15);Amiot, A.(16);Simon, M.(17);Caillo, L.(18);Hébuterne, X.(19);Vidon, M.(20);Benezech, A.(21);Elgharabawy , Y.(22);Peyrin-biroulet, L.(23);

Created: Friday, 14 July 2023, 10:43 AM

DOP89: Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease

Year: 2022

Source: ECCO'22

Authors: Wang, Z.(1);Kantasiripitak, W.(1);Verstockt, B.(2,3);João, S.(2,3);Ferrante, M.(2,3);Declerck, P.(1);D’Haens, G.(4);Laharie, D.(5);Vermeire, S.(2,3);Dreesen, E.(1);

Created: Friday, 11 February 2022, 3:52 PM

DOP90 The role of Nlrp9b, a novel NLR member in regulating experimental colitis

Year: 2020

Source:

ECCO'20 Vienna

Authors:

D. Zheng^1,2, M. Levy¹, E. Elinav¹

Created: Thursday, 30 January 2020, 10:12 AM

DOP90: Amphiregulin promotes colitis-associated intestinal fibrosis through activation of PI3K/AKT signaling in Intestinal fibroblasts

Year: 2024

Source: ECCO'24 Stockholm

Authors: Zhao, Xiaojing

Created: Tuesday, 30 April 2024, 5:03 PM

DOP90: Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial

Year: 2022

Source: ECCO'22

Authors: Peyrin-Biroulet, L.(1);Vermeire, S.(2);D'Haens, G.R.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Le Bars, M.(8);Lahaye , M.(9);Nazar, M.(10);Ni, L.(11);Bravatà , I.(12);Lavie , F.(9);Daperno , M.(13);Lukáš , M.(14);Armuzzi , A.(15);Löwenberg , M.(3);Gaya , D.R.(16);Danese , S.(17); STARDUST

Created: Friday, 11 February 2022, 3:52 PM

DOP90: Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 years

Year: 2021

Source: ECCO'21 Virtual

Authors: Ricciuto, A.(1);Lamb, C.(2,3);Benchimol, E.I.(1);Walker, G.(4);Kennedy, N.(5,6);Kuenzig, M.E.(1);Kaplan, G.(7);Griffiths, A.M.(1);Reinisch, W.(8);Sebastian, S.(9,10)

Created: Wednesday, 2 June 2021, 4:12 PM

DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Remo Panaccione

Created: Friday, 14 July 2023, 2:22 PM

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Panaccione, R.(1)*;Sapin, C.(2);Chan-Diehl, F.W.(3);Moses, R.E.(3);Siegmund, B.(4);Walsh, A.(5);Kobayashi, T.(6);Parambir, D.S.(7);Travis, S.(8);

Created: Friday, 14 July 2023, 10:43 AM

DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD. Results after 20 years of follow-up in the IBSEN study.

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Alvilde Ossum

Created: Tuesday, 28 May 2019, 3:32 PM

Epidemiology, Crohn’s disease, Ulcerative colitis, Patient reported outcomes, Arthralgia, Sacroileitis, Other extraintestinal manifestations, Psychological co-morbidity, Fatigue, Patient reported outcomes

Files: 1

DOP90: The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD: results after 20 years of follow-up in the IBSEN study

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

A. Ossum*^1,2, Ø. Palm³, M. Cvancarova⁴, B. Moum^1,2, M. L. Høivik¹, The IBSEN study group¹

Created: Friday, 22 February 2019, 9:41 AM